Desonide Cream, 0.05 percent, is a low-potency corticosteroid drug used for the treatment of skin disorders . Desonide Cream, 0.05 percent, has a predicted market value of USD 12 million for the twelve months ending September 2022 .
New Delhi (India), December 9 : Alembic Pharmaceuticals (Alembic) reported on Friday that the US Food and Drug Administration (USFDA) had given the company's abbreviated new drug application (ANDA)-Desonide Cream, 0.05 percent, an ointment used for the treatment of skin disorders.According to a statement released by the company, Aleor Dermaceuticals (Aleor) filed the ANDA.The accepted ANDA is therapeutically equivalent to the reference listed drug product (RLD), Desonide Cream, 0.05 percent, of Padagis US LLC.Desonide Cream, 0.05 percent, is a low-potency corticosteroid drug used for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.According to pharma firm IQVIA, Desonide Cream, 0.05 percent, has a predicted market value of USD 12 million for the twelve months ending September 2022.Alembic is a vertically integrated research and development (R-D) pharmaceutical company that has been at the forefront of health care since 1907.